Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PPM1B | O75688 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377565 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL21814272 | 0.85 | KEAP1 (0.58) | ALDH1A1KDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL1194676 | 0.83 | HSD17B1 (0.38) | ALDH1A1KDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL14236427 | 0.79 | KDM4E (0.33) | ALDH1A1KDM4EHPGDHSD17B10AKR1C3 | |
| SCHEMBL1194761 | 0.79 | PTPN1 (0.34) | ALDH1A1KDM4EHPGDHSD17B10AKR1C3 | |
| SCHEMBL22628276 | 0.78 | AKR1C2 (0.44) | ALDH1A1KDM4EKEAP1AKR1C3AKR1C2 | |
| SCHEMBL1633725 | 0.77 | RXRB (0.46) | ALDH1A1KDM4EHPGDHSD17B10AKR1C3 | |
| SCHEMBL2342293 | 0.77 | TSHR (0.57) | ALDH1A1KDM4ETDP1AKR1C3AKR1C2 | |
| SCHEMBL31046844 | 0.75 | AKR1C3 (0.39) | ALDH1A1ALOX15AKR1C3AKR1C2PTGS2 | |
| SCHEMBL2348838 | 0.74 | PTGS2 (0.44) | ALDH1A1KDM4EHPGDHSD17B10AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2024-12-24 | — | — | US | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2022-08-23 | — | — | US | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| CN-114042070-A | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-112004802-B | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-10618886-B1 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. (KY) | 2020-04-14 | — | — | US | disclosed |
| US-20200102289-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-04-02 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| EP-2242740-B1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-12-12 | — | — | EP | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| WO-2009097972-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102289-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | ALDH1A1 1370/4885KDM4E 2153/4885HPGD 382/4885 |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | ALDH1A1 1448/4885KDM4E 2022/4885HPGD 448/4885 |
| US-10618886-B1 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ALDH1A1 1370/4885KDM4E 2153/4885HPGD 382/4885 |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ALDH1A1 1370/4885KDM4E 2153/4885HPGD 382/4885 |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | ALDH1A1 245/4885KDM4E 3158/4885HPGD 2345/4885 |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | ALDH1A1 1370/4885KDM4E 2153/4885HPGD 382/4885 |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL1, F2RL3 | ALDH1A1 3141/4885KDM4E 3732/4885HPGD 794/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | ALDH1A1 245/4885KDM4E 3158/4885HPGD 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.